STOCK TITAN
  1. Home
  2. News
  3. CMPX

Compass Therapeutics, Inc. - $CMPX STOCK NEWS

Welcome to our dedicated page for Compass Therapeutics news (Ticker: $CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Compass Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Compass Therapeutics's position in the market.

News
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Rhea-AI Summary

Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place in New York City on May 20, 2024, with a fireside chat scheduled for 11:30 AM ET. A webcast of the chat will be available live and archived for 90 days on the company's events page. Compass Therapeutics specializes in developing antibody-based therapeutics aimed at treating various human diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
conferences
-
News
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Rhea-AI Summary

Compass Therapeutics, Inc. (Nasdaq: CMPX) reported their first quarter 2024 financial results and provided a business update. They received FDA Fast Track Designation for CTX-009 for the treatment of biliary tract tumors. Enrollment is progressing well in their clinical trials. They ended the quarter with $156 million in cash and marketable securities, extending their cash runway into late 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
earnings
-
News
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Rhea-AI Summary
Compass Therapeutics receives FDA Fast Track Designation for CTX-009 in combination with Paclitaxel for treating metastatic or locally advanced Biliary Tract Tumors. The bispecific antibody has shown promising clinical responses in Phase 2 study. Top-line data for COMPANION-002 study expected by end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Rhea-AI Summary
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
clinical trial
-
News
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) announces poster presentations on CTX-009, a bispecific antibody, at the Cholangiocarcinoma Foundation 2024 Annual Conference. The presentations focus on patient selection hypotheses using real-world data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
News
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) will participate in the Stifel Targeted Oncology Days virtually on April 16-17, 2024, presenting their antibody-based therapeutics for various human diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
conferences
News
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Compass Therapeutics, Inc. provided an update on their clinical trials for CTX-009, CTX-471, and CTX-8371, reporting progress in enrollment and potential biomarkers. Financially, the company ended 2023 with $152 million in cash and marketable securities, extending their cash runway into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
earnings
-
News
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) will participate in the Leerink Partners Global Biopharma Conference on March 13, 2024, to showcase its antibody-based therapeutics for human diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
conferences
-
News
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
Rhea-AI Summary
Compass Therapeutics, Inc. (Nasdaq: CMPX) announces the publication of a peer-reviewed article on CTX-8371, a bispecific checkpoint inhibitor showing enhanced anti-tumor activity. The data revealed a unique mechanism-of-action targeting PD-1 and PD-L1, leading to increased efficacy in experimental models. The combination with CTX-471 further improved anti-tumor effects, indicating promising potential for proprietary combination therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
clinical trial
News
Compass Therapeutics Provides Corporate Update
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) reported a business update, including progress in clinical trials for CTX-009 in biliary tract and colorectal cancer, positive clinical activity in the Phase 1b study of CTX-471, and FDA acceptance of the CTX-8371 IND. The company also announced a CEO succession plan and ended 2023 with an estimated $152 million in cash and marketable securities, providing cash runway into mid-year 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.16%
Tags
none
Stock CMPX logo
Compass Therapeutics, Inc.

Nasdaq:CMPX

CMPX Rankings

#3719 Ranked by Market Cap
#4567 Ranked by Stock Gains
N/A Ranked by Dividends

CMPX Stock Data

220.14M
102.85M
13.44%
62.82%
1.18%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About CMPX

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond